# US 2024/0189323 A1 · Preparation for ethinylestradiol-cyclodextrin complex and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189323 A1
- Document ID: US20240189323A1
- Status: Published application
- Kind: A1
- Application number: 18/555,321
- Filed: 2023-01-18
- Published: 2024-06-13
- Earliest claimed: 2022-01-29
- Assignees: National Research Institute for Family Planning
- Applicants: National Research Institute for Family Planning
- Inventors: Juan XU; Lifeng NING; Bin HE
- Web page: https://patentgrep.com/patent/US20240189323A1

## CPC

- A61K 31/567: substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- C08B 37/0015: {Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes}
- C08L 5/16: Cyclodextrin; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

Disclosed are preparation for an ethinylestradiol-cyclodextrin complex and use thereof. The ethinylestradiol-cyclodextrin complex utilizes the properties of cyclodextrin that the inner cavity is hydrophobic and the outer surface is hydrophilic to increase the water solubility of the ethinylestradiol-cyclodextrin complex that is also an ethinylestradiol drug, so that the solubility of ethinylestradiol is greatly increased and the bioavailability of water-insoluble ethinylestradiol is improved, thereby providing the possibility for changing the administration mode and homogeneous injection of ethinylestradiol.

## Claims

### Claim at position 1

1-12. (canceled)

### Claim 13

A pharmaceutical composition, comprising ethinylestradiol and cyclodextrin, wherein the ethinylestradiol and the cyclodextrin interact to form a clathrate, and the cyclodextrin is selected from ethylenediamine-β-cyclodextrin, diethylenetriamine-β-cyclodextrin, triethylenetetramine-β-cyclodextrin, tetraethylenepentamine-β-cyclodextrin, and hydroxypropyl-β-cyclodextrin.

### Claim 14 (depends on 13)

The pharmaceutical composition according to claim 13, wherein the β-cyclodextrin derivative is selected from diethylenetriamine-β-cyclodextrin.

### Claim 15 (depends on 13)

The pharmaceutical composition according to claim 13, wherein the cyclodextrin and the ethinylestradiol have a stoichiometric ratio of 1:1.

### Claim 16 (depends on 13)

The pharmaceutical composition according to claim 13, wherein a preparation method for the clathrate is as follows:
dissolving the cyclodextrin in deionized water, adding the ethinylestradiol and a co-solvent, heating and stirring the mixture; then continuously stirring the mixture at room temperature and keeping the mixture overnight at low temperature; filtering the mixture, and drying to give a white solid powder.

### Claim 17 (depends on 16)

The pharmaceutical composition according to claim 16, wherein the co-solvent is ethanol.

### Claim 18 (depends on 16)

The pharmaceutical composition according to claim 16, wherein the drying is freeze drying.

### Claim 19 (depends on 14)

The pharmaceutical composition according to claim 14, wherein a preparation method for the diethylenetriamine-β-cyclodextrin is as follows:
1) dissolving β-cyclodextrin in a sodium hydroxide solution to give an alkaline β-cyclodextrin solution;
2) dissolving toluenesulfonyl chloride in acetonitrile, adding the mixture to the alkaline β-cyclodextrin solution described above, adjusting the pH to give a suspension, obtaining a precipitate at low temperature, and drying to give 6-p-toluenesulfonyl-β-cyclodextrin;
3) dissolving the 6-p-toluenesulfonyl-β-cyclodextrin in N-methylpyrrolidone, heating, adding potassium iodide and diethylenetriamine, stirring the mixture at high temperature under nitrogen atmosphere, then cooling to room temperature, collecting a precipitate, and drying to give the diethylenetriamine-β-cyclodextrin.

### Claim 20 (depends on 19)

The pharmaceutical composition according to claim 19, wherein the pH is adjusted to 5-7 with hydrochloric acid in 2).

### Claim 21 (depends on 19)

The pharmaceutical composition according to claim 19, wherein the suspension in 2) is at 4° C. overnight to give a precipitate.

### Claim 22 (depends on 19)

The pharmaceutical composition according to claim 19, wherein the precipitate in 2) is washed with ethanol.

### Claim 23 (depends on 19)

The pharmaceutical composition according to claim 19, wherein the drying is at 50° C. to give 6-p-toluenesulfonyl-β-cyclodextrin in 2).

### Claim 24 (depends on 19)

The pharmaceutical composition according to claim 19, wherein the mixture is stirred at 70° ° C. under nitrogen atmosphere in 3).

### Claim 25 (depends on 19)

The pharmaceutical composition according to claim 19, wherein the precipitate is collected using suction filtration in 3).

### Claim 26 (depends on 19)

The pharmaceutical composition according to claim 19, wherein the precipitate in 3) is dried under vacuum.

### Claim 27 (depends on 13)

The pharmaceutical composition according to claim 13, further comprising a pharmaceutically acceptable carrier.

### Claim 28 (depends on 13)

A method for preparing the pharmaceutical composition according to claim 13, comprising: dissolving the cyclodextrin in deionized water, adding the ethinylestradiol and a co-solvent, heating and stirring the mixture; then continuously stirring the mixture at room temperature and keeping the mixture overnight at low temperature; filtering the mixture, and drying to give a white solid powder.

### Claim 29 (depends on 13)

A method for increasing the solubility of ethinylestradiol and improving the release performance of the ethinylestradiol, wherein the pharmaceutical composition according to claim 13 is prepared.

### Claim 30 (depends on 13)

A method for contraception or for treating a gynecological disease, comprising administering to a subject in need thereof an effective amount of the pharmaceutical composition according to claim 13.

### Claim 31 (depends on 30)

The method according to claim 30, wherein the subject is a mammal.

### Claim 32 (depends on 31)

The method according to claim 31, wherein the mammal includes a human, a non-human primate, a rabbit, a sheep, a rat, a dog, a cat, a pig, or a mouse.
